Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
BMRN
BMRN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BMRN News
BioMarin Pharmaceutical Outlines Strategic Refresh and Market Outlook
3d ago
Yahoo Finance
FDA Grants Approvals for Multiple New Therapies
4d ago
NASDAQ.COM
UniQure's Gene Therapy Faces FDA Challenges
4d ago
CNBC
FDA Faces Criticism Amid Innovation Challenges
6d ago
CNBC
BioMarin's Drug Approved by FDA for PKU Treatment
Mar 02 2026
Benzinga
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
Feb 28 2026
NASDAQ.COM
FDA Approves PALYNZIQ for Pediatric PKU Treatment in Adolescents
Feb 28 2026
PRnewswire
FDA Approves PALYNZIQ for Adolescent PKU Treatment
Feb 28 2026
Newsfilter
FDA Grants Approval for Biomarin's Palynziq® (Pegvaliase-PQPZ) for Adolescents Aged 12 and Up with Phenylketonuria (PKU)
Feb 28 2026
moomoo
BioMarin Reports Mixed Q4 Results with Earnings Miss
Feb 25 2026
Benzinga
BioMarin Reports Strong 2025 Earnings Growth
Feb 24 2026
seekingalpha
BioMarin Pharmaceutical Q4 Earnings Beat Expectations Despite EPS Miss
Feb 23 2026
seekingalpha
BioMarin to Host Q4 2025 Earnings Call on February 23, 2026
Feb 23 2026
NASDAQ.COM
BioMarin Pharmaceutical Set to Release Q4 Earnings on February 23
Feb 20 2026
seekingalpha
Phenylketonuria Treatment Market Outlook Analysis
Feb 18 2026
Newsfilter
BioMarin to Host Q4 2025 Earnings Call on February 23, 2026
Feb 17 2026
PRnewswire
Show More News
